Akero Therapeutics Inc - AKRO Quarterly EPS earnings growth

Akero Corp - graphic logo of issuer AKRO

Akero Therapeutics (AKRO) is developing a portfolio of treatments for metabolic pathologies, mitigating risks through multiple clinical programs. This chart on the GURU.Markets platform shows a quarterly EPS growth marker demonstrating the company's adaptation to challenges, with the value holding at 5.10. However, a failure of the lead drug could trigger a collapse in market capitalization, while the lack of revenue causes a cash deficit and a need for further investment.

Akero (AKRO) - Year-over-year earnings per share growth for the last twelve months from 07/04/2022 to 12/20/2025

Financial and market metric breakdowns for Akero Therapeutics (AKRO)

- share price and consensus valuation forecast:
Analysis of all company metrics:Akero Therapeutics
Manufactured product of Akero Corp

Searching for sustainable assets requires separating market noise from real financial dynamics. This indicator measures the percentage change in net earnings per share per quarter, reflecting the efficiency of business capitalization. For Akero Therapeutics (AKRO), this metric correlates directly with the burn rate for the development of MASH drugs. The current value of 5.10 allows for an assessment of the company's financial stability amidst clinical trials. By analyzing the quarterly earnings per share growth rate, an investor can forecast liquidity risks.

Competitors of Akero Therapeutics (AKRO)

ASND (Ascendis Pharma) - Year-over-year net earnings per share growth for the last 12 months|MDGL: Year-over-year earnings per share growth rate for the last twelve months|CORT (Corcept Therapeutics Corp) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Rhythm Pharmaceuticals|Quarterly EPS earnings growth MTSR|Year-over-year earnings per share growth for the last twelve months MLTX (MoonLake Immunotherapeutics AG)|Year-over-year earnings per share growth for the last twelve months crinetics.com CRNX|NewAmsterdam Pharma Corp (NAMS) - Earnings per share growth in annualized terms for the last twelve months|SLNO - Year-over-year earnings per share growth for the last twelve months|FOLD: Year-over-year earnings per share growth for the last twelve months|ETNB: Quarterly EPS earnings growth|AGIO - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Structure Corp|MiMedx Corp (MDXG) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months rezolutebio.com (RZLT)|Year-over-year net earnings per share growth for the last 12 months lexpharma.com LXRX|Quarterly EPS earnings growth MBX (MBX Biosciences)|Altimmune Corp - Year-over-year earnings per share growth for the last twelve months|Aardvark Therapeutics Inc. - Quarterly EPS earnings growth|SGMT - Quarterly EPS earnings growth|BioAge Labs (BIOA) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months biomeafusion.com (BMEA)|Year-over-year earnings per share growth for the last twelve months Quince Therapeutics, Inc.|Year-over-year net earnings per share growth for the last 12 months Fractyl (GUTS)|Year-over-year net earnings per share growth for the last 12 months VTVT (vTv Therapeutics Inc.)|ATPC - Earnings per share growth in annualized terms for the last twelve months|Pluri Inc. - Year-over-year net earnings per share growth for the last 12 months|Net earnings per share growth for the trailing year Synlogic Corp|LPCN - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months Matinas BioPharma Holdings, Inc. MTNB|SPRB: Quarterly EPS earnings growth|Galecto Corp - Year-over-year earnings per one share growth for the last 12 months|CTCX (carmellrx.com) - Quarterly EPS earnings growth|Quarterly EPS earnings growth lumos-pharma.com|Quarterly EPS earnings growth ONVO|Year-over-year net earnings per share growth for the last 12 months Radius Health RDUS